

Claims

1 A method of treating or preventing pulmonary hypertension in a patient which comprises treating the patient with an effective amount of a PDE5 inhibitor selected from the group:


- a) sildenafil;
- b) (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;
- c) 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- d)

e)

; and

17

g)



or a pharmaceutically acceptable salt, solvate or polymorph; or a pharmaceutical composition thereof.

5

2

A method according to claim 1 wherein the PDE5 inhibitor is sildenafil.

1

A method according to claim 1 or 2 wherein the effective amount is less than 50 mg per day.

1

A method according to claim 1 or 2 wherein the effective amount is up to 10 mg per day.

A method according to claim 1 or 2 wherein the effective amount is from 1 to 10 mg per day.

20

A method according to any preceding claim wherein the PDE5 inhibitor is administered orally.

8




A method according to claim 7 wherein the PDE5 inhibitor is sildenafil citrate.

10

A method according to claim 9 wherein the PDE5 inhibitor is sildenafil mesylate.


11 The use of a PDE5 inhibitor selected from the group:

- a) sildenafil;
- b) (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;
- 5 c) 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- d)



; and





or a pharmaceutically acceptable salt, solvate or polymorph thereof; for the manufacture of a medicament for treating or preventing pulmonary hypertension.

5 12 The use according to claim 11 wherein the PDE5 inhibitor is sildenafil.

13 The use according to claim 11 or 12 wherein the effective amount is less than 50 mg per day.

10 14 The use according to claim 11 or 12 wherein the effective amount is up to 20 mg per day.

15 The use according to claim 11 or 12 wherein the effective amount is up to 10 mg per day.

15 16 The use according to claim 11 or 12 wherein the effective amount is from 1 to 10 mg per day.

20 17 The use according to any one of claims 11 to 16 wherein the PDE5 inhibitor is administered orally.

18 The use according to claim 17 wherein the PDE5 inhibitor is sildenafil citrate.

19 The use according to any one of claims 11 to 16 wherein the PDE5 inhibitor is inhaled.

25 20 The use according to claim 19 wherein the PDE5 inhibitor is sildenafil mesylate.

(W.C.2)